Table 2.
Prothrombin complex concentrate for management of major bleeding in patients receiving apixaban or rivaroxaban
| Majeed et al24 (N = 84) | Schulman et al25 (N = 66) | |
|---|---|---|
| Design | Cohort, prospective enrollment | Cohort, prospective enrollment |
| Treatment | 4-Factor PCC | 4-Factor PCC |
| <65 kg, 1500 units | 2000 units | |
| >65 kg, 2000 units | ||
| Time from factor Xa inhibitor, median (IQR) | 12 h (9–16) | 18 h (12–21) |
| Hemostatic effectiveness, n (%) | 58 (69) | — |
| Good | — | 43 (65) |
| Moderate | — | 13 (20) |
| Poor/none | — | 10 (15) |
| Thromboembolism, n (%) | 3 (4) | 5 (8) |
| Death, n (%) | 27 (32) | 9 (14) |
| Restart of oral anticoagulants, n (%) | NA | 41 (62)* |
IQR, interquartile range; NA, not available; PCC, prothrombin complex concentrate.
*
Parenteral or oral anticoagulants (unknown dosing).